Department of Pathology, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, KARNATAKA, INDIA.
Turk Patoloji Derg. 2024;40(2):122-127. doi: 10.5146/tjpath.2024.13052.
The classification of renal tumors is expanding with the addition of new molecular entities in the 5th World Health Organization classification. Apart from this, the major updates in the definition of papillary renal cell carcinoma are that these tumors are no longer subtyped into type 1 and type 2. In oncocytic tumors, the new molecularly defined renal tumors, emerging and novel entities need to be considered in the diagnosis of oncocytic and chromophobe renal tumors.
This is a retrospective study to review and reclassify papillary, oncocytic, and chromophobe renal tumors based on the new WHO classification and correlate with clinical data, gross, microscopic features, and immunohistochemistry markers.
A total of thirteen cases were reviewed and the tumor grade was changed for three out of four cases of papillary renal cell carcinoma and a single case was recategorized and graded. In nine cases of oncocytic and chromophobe renal tumors, the diagnoses were modified in 3 cases.
Newly defined molecular renal tumors require advanced immunohistochemistry markers and molecular tests. This poses diagnostic challenges to pathologists practicing in low resource settings where molecular tests are not available.
随着第五版世界卫生组织分类中新增的分子实体，肾肿瘤的分类正在不断扩展。除此之外，乳头状肾细胞癌定义的主要更新是，这些肿瘤不再分为 1 型和 2 型。在嗜酸细胞瘤中，新的分子定义的肾肿瘤，新兴和新实体需要在嗜酸细胞瘤和嫌色细胞瘤的诊断中考虑。
这是一项回顾性研究，根据新的世卫组织分类对乳头状、嗜酸细胞瘤和嫌色细胞瘤进行复习和重新分类，并与临床数据、大体和显微镜特征以及免疫组织化学标志物进行相关性分析。
共回顾了 13 例病例，其中 4 例乳头状肾细胞癌中有 3 例肿瘤分级发生改变，1 例病例重新分类和分级。在 9 例嗜酸细胞瘤和嫌色细胞瘤中，有 3 例诊断发生了改变。
新定义的分子肾肿瘤需要先进的免疫组织化学标志物和分子检测。这给在没有分子检测的资源有限的环境中工作的病理学家带来了诊断挑战。
